Camp4 Therapeutics Corp (CAMP)

$4.52 +0.18 (4.15%)
Market Cap 203.46M
Revenue (ttm) 650,000.00
Net Income (ttm) -51.79M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -7,967.69%
Debt to Equity Ratio 0.00
Volume 36,900
Avg Vol 176,760
Day's Range N/A - N/A
Shares Out 46.88M
Stochastic %K 57%
Beta 0.66
Analysts Strong Sell
Price Target $8.75

Company Profile

Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops regulatory RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-CPS-001, which is in a Phase 1 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-SYNGAP for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeuti...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 651 8867
Address:
One Kendall Square, 3rd Floor Building 1400 West, Cambridge, United States
_Crocodileteeth
_Crocodileteeth Feb. 24 at 12:35 AM
Special thanks to @SqueezeSharkie for nailing that trade, He is worth Following for sure 💯 $CAMP $ORIC $AUST $RMSG ++
0 · Reply
RodneyHammons200
RodneyHammons200 Feb. 21 at 7:17 AM
$CAMP CalAmp provides telematics and fleet solutions. Revenue depends on subscription growth. Turnaround execution remains critical.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 20 at 7:32 PM
$CAMP RSI: 63.04, MACD: -0.1605 Vol: 0.37, MA20: 4.00, MA50: 5.15 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
LunarWatcher
LunarWatcher Feb. 18 at 7:49 AM
$CAMP CalAmp provides IoT solutions for fleet and asset tracking, facing turnaround after restructuring with competitive pressures [citation:historical].
0 · Reply
Justrise07
Justrise07 Feb. 17 at 4:27 PM
$OCUL tecover your loss with $CAMP 3x buyout coming $GSK
0 · Reply
Justrise07
Justrise07 Jan. 27 at 6:34 PM
$GSK are you buying $CAMP therapudics , what’s going on ?
0 · Reply
garygb
garygb Jan. 23 at 5:15 PM
$CAMP Near a bottom.
0 · Reply
topstockalerts
topstockalerts Jan. 2 at 9:40 PM
After Hours Top Gainers $GHRS $CUE $PRE $PASW $CAMP
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 1 at 2:44 AM
$CAMP RSI: 56.08, MACD: 0.5362 Vol: 1.24, MA20: 5.58, MA50: 4.52 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
TARPTrader
TARPTrader Dec. 25 at 10:38 AM
$CAMP The opportunity set remains meaningful, but only if discipline keeps pace with ambition. Execution reliability across quarters will determine whether confidence can compound. Demonstrating resilience under stress would materially support valuation. Future re‑rating depends on tightening the gap between narrative and reality.
0 · Reply
Latest News on CAMP
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Feb 20, 2026, 4:05 PM EST - 3 days ago

CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Camp4 Therapeutics Corporation (CAMP) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 14, 2026, 11:45 PM EST - 5 weeks ago

Camp4 Therapeutics Corporation (CAMP) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

CAMP4 to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 8:00 AM EST - 6 weeks ago

CAMP4 to Present at the 44th Annual J.P. Morgan Healthcare Conference

CAMP4 Announces Pricing of $30.0 Million Underwritten Offering of Common Stock

Dec 18, 2025, 7:10 AM EST - 2 months ago

CAMP4 Announces Pricing of $30.0 Million Underwritten Offering of Common Stock

CAMP4 and GSK Enter Strategic Collaboration to Advance RNA-Based Therapeutic Discoveries

Dec 18, 2025, 7:00 AM EST - 2 months ago

CAMP4 and GSK Enter Strategic Collaboration to Advance RNA-Based Therapeutic Discoveries

CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 12, 2025, 4:05 PM EST - 2 months ago

CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMP4 Reports Third Quarter 2025 Financial Results and Corporate Highlights

Nov 6, 2025, 4:05 PM EST - 3 months ago

CAMP4 Reports Third Quarter 2025 Financial Results and Corporate Highlights

CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01

Oct 1, 2025, 8:00 AM EDT - 5 months ago

CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01

CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders

Sep 10, 2025, 7:00 AM EDT - 5 months ago

CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders

CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights

Aug 14, 2025, 4:05 PM EDT - 6 months ago

CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights

CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American Society of Gene and Cell Therapy Annual Meeting

May 16, 2025, 6:00 AM EDT - 10 months ago

CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American Society of Gene and Cell Therapy Annual Meeting

CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights

May 13, 2025, 4:05 PM EDT - 10 months ago

CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights

CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting

Apr 28, 2025, 4:30 PM EDT - 10 months ago

CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q2

Apr 10, 2025, 6:56 AM EDT - 11 months ago

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q2

EWTX

CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update

Mar 27, 2025, 4:05 PM EDT - 11 months ago

CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update

CAMP4 Appoints Multiple Industry Veterans to its Board of Directors

Mar 18, 2025, 8:00 AM EDT - 1 year ago

CAMP4 Appoints Multiple Industry Veterans to its Board of Directors

CORRECTION - CalAmp Synovia to Showcase Leading Student Transportation Solutions at STN East 2025

Mar 13, 2025, 10:39 PM EDT - 1 year ago

CORRECTION - CalAmp Synovia to Showcase Leading Student Transportation Solutions at STN East 2025

CalAmp Synovia to Showcase Leading Student Transportation Solutions at STN East 2025

Mar 13, 2025, 2:58 PM EDT - 1 year ago

CalAmp Synovia to Showcase Leading Student Transportation Solutions at STN East 2025

CAMP4 to Participate in Upcoming Investor Conferences

Feb 6, 2025, 8:00 AM EST - 1 year ago

CAMP4 to Participate in Upcoming Investor Conferences

CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones

Jan 7, 2025, 4:05 PM EST - 1 year ago

CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones

CAMP4 to Participate in the Piper Sandler 36th Annual Healthcare Conference

Dec 2, 2024, 8:00 AM EST - 1 year ago

CAMP4 to Participate in the Piper Sandler 36th Annual Healthcare Conference

CAMP4 Reports Third Quarter 2024 Financial Results

Nov 21, 2024, 4:05 PM EST - 1 year ago

CAMP4 Reports Third Quarter 2024 Financial Results

CAMP4 Analyst Highlights Rare Disease Platform Potential

Nov 5, 2024, 3:06 PM EST - 1 year ago

CAMP4 Analyst Highlights Rare Disease Platform Potential

CAMP4 Announces Pricing of Initial Public Offering

Oct 10, 2024, 7:07 PM EDT - 1 year ago

CAMP4 Announces Pricing of Initial Public Offering

Camp4 Therapeutics Targets IPO On Early Positive Results

Oct 1, 2024, 4:30 PM EDT - 1 year ago

Camp4 Therapeutics Targets IPO On Early Positive Results

_Crocodileteeth
_Crocodileteeth Feb. 24 at 12:35 AM
Special thanks to @SqueezeSharkie for nailing that trade, He is worth Following for sure 💯 $CAMP $ORIC $AUST $RMSG ++
0 · Reply
RodneyHammons200
RodneyHammons200 Feb. 21 at 7:17 AM
$CAMP CalAmp provides telematics and fleet solutions. Revenue depends on subscription growth. Turnaround execution remains critical.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 20 at 7:32 PM
$CAMP RSI: 63.04, MACD: -0.1605 Vol: 0.37, MA20: 4.00, MA50: 5.15 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
LunarWatcher
LunarWatcher Feb. 18 at 7:49 AM
$CAMP CalAmp provides IoT solutions for fleet and asset tracking, facing turnaround after restructuring with competitive pressures [citation:historical].
0 · Reply
Justrise07
Justrise07 Feb. 17 at 4:27 PM
$OCUL tecover your loss with $CAMP 3x buyout coming $GSK
0 · Reply
Justrise07
Justrise07 Jan. 27 at 6:34 PM
$GSK are you buying $CAMP therapudics , what’s going on ?
0 · Reply
garygb
garygb Jan. 23 at 5:15 PM
$CAMP Near a bottom.
0 · Reply
topstockalerts
topstockalerts Jan. 2 at 9:40 PM
After Hours Top Gainers $GHRS $CUE $PRE $PASW $CAMP
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 1 at 2:44 AM
$CAMP RSI: 56.08, MACD: 0.5362 Vol: 1.24, MA20: 5.58, MA50: 4.52 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
TARPTrader
TARPTrader Dec. 25 at 10:38 AM
$CAMP The opportunity set remains meaningful, but only if discipline keeps pace with ambition. Execution reliability across quarters will determine whether confidence can compound. Demonstrating resilience under stress would materially support valuation. Future re‑rating depends on tightening the gap between narrative and reality.
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 22 at 2:56 PM
$CAMP
0 · Reply
StockScanners
StockScanners Dec. 20 at 6:46 PM
$CAMP reached 8.44
0 · Reply
OpenOutcrier
OpenOutcrier Dec. 18 at 2:07 PM
$CAMP (-8.8% pre) CAMP4 Announces Pricing of $30.0 Million Underwritten Offering of Common Stock https://ooc.bz/l/87897
0 · Reply
xUltraCash
xUltraCash Dec. 18 at 12:16 PM
$CAMP give me 7.80…
0 · Reply
DARKP00L
DARKP00L Dec. 18 at 12:09 PM
$CAMP 07:03 on Dec. 18 2025 CAMP4 Therapeutics Enters Into Strategic Research, Collaboration And License Agreement With GSK To Identify, Develop ASO Drug Candidates For Multiple Gene Targets Relevant To Neurodegenerative And Kidney Disease Indications #tradeideas
0 · Reply
typhoonfish
typhoonfish Dec. 15 at 4:44 PM
$CAMP There was actually a few trades at $11 this morning .
0 · Reply
StockScanners
StockScanners Dec. 13 at 9:03 PM
$CAMP reached 6.60
0 · Reply
theflynews
theflynews Dec. 12 at 4:12 PM
Biotech Alert: Searches spiking for these stocks today - $CAMP - https://thefly.com/permalinks/entry.php/CAMPid4255975?1765555207C38
0 · Reply
HighReturnStocks
HighReturnStocks Dec. 11 at 3:42 PM
$CAMP 115% gains for followers hope yall enjoyed this call, Still swinging $BYND and added $ORCL on the dip today.
0 · Reply
StockScanners
StockScanners Dec. 11 at 2:15 AM
$CAMP keep watch if this holds above 4.90
0 · Reply